Abstract
Assisted ventilation and hospitalization are significant drivers of aggregate annual costs and overall health burden in amyotrophic lateral sclerosis (ALS). An oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol (PB&TURSO) slowed functional decline in people living with ALS in the 6-month randomized, placebo-controlled phase of the CENTAUR trial. Here, we report final analyses of ALS progression events in CENTAUR inclusive of the long-term, follow-up open-label extension phase.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call